SPY757.07−0.36%QQQ685.05−0.77%BTC/USD73,778.94+0.11%DIA524.43−0.00%GLD364.69−0.13%TLT81.02+0.12%

Aprea Therapeutics Inc

APRENASDAQ

Trade with Public

$0.4445

-0.0011-0.25%

Last update: Nov 11, 9:27 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Earnings: Q3 2026 Earnings were released on Wed Nov 4th, before the market open

Aprea Therapeutics (APRE) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Aprea Therapeutics (APRE) stock.

Analyst Consensus — 4 Analysts

4Buy

# Analysts4

Latest Upgrades and Downgrades for Aprea Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$2
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$6→$3
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$7→$6
—	Oppenheimer	Matthew Biegler	Initiate	Outperform	$5
—	Wedbush	Robert Driscoll	Maintained	Outperform	$7
—	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$4→$1
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$11→$7
—	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$5→$4
—	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$20→$5
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	Wedbush	Robert Driscoll	Maintained	Outperform	$11
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$9→$11
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20

Aprea Therapeutics Inc

Aprea Therapeutics (APRE) Stock Price Target 2026

Latest Upgrades and Downgrades for Aprea Therapeutics Stock

Aprea Therapeutics (APRE) Stock Price Target 2026

Latest Upgrades and Downgrades for Aprea Therapeutics Stock

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

Aprea Therapeutics Inc

Aprea Therapeutics (APRE) Stock Price Target 2026

Latest Upgrades and Downgrades for Aprea Therapeutics Stock

Aprea Therapeutics (APRE) Stock Price Target 2026

Latest Upgrades and Downgrades for Aprea Therapeutics Stock

Analyst Ratings News

PROLadenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROOppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PROWedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROLadenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROOppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PROWedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target